blank Quick help
blank Maintenance news
blank News flashes
blank Related links

Extract from the Register of European Patents

EP About this file: EP2861233

EP2861233 - TRANSDERMAL HORMONE REPLACEMENT THERAPIES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  11.09.2020
Database last updated on 05.05.2025
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
TherapeuticsMD, Inc.
951 Yamato Road, Suite 220
Boca Raton, FL 33431 / US
[2019/44]
Inventor(s)01 / BERNICK, Brian A.
17601 Middlebrook Way
Boca Raton, Florida 33496 / US
02 / AMADIO, Julia M.
1110 Walnut Terrace
Boca Raton, FL 33486 / US
03 / PERSICANER, Peter H.R.
17070 Royal Cove Way
Boca Raton, Florida 33496 / US
04 / CACACE, Janice Louise
8442 6th St N
St Petersburg, FL 33702 / US
05 / IRANI, Neda
1703 Silverleaf Oak Court
Palm Beach Gardens, Florida 33410 / US
 [2015/22]
Representative(s)Murgitroyd & Company
165-169 Scotland Street
Glasgow G5 8PL / GB
[N/P]
Application number, filing date13807463.818.06.2013
[2019/45]
WO2013US46444
Priority number, dateUS201261661302P18.06.2012         Original published format: US 201261661302 P
US201261662265P20.06.2012         Original published format: US 201261662265 P
US20121368400221.11.2012         Original published format: US201213684002
WO2013US2330925.01.2013         Original published format: PCT/US2013/023309
US20131384336215.03.2013         Original published format: US201313843362
[2015/17]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013192250
Date:27.12.2013
Language:EN
[2013/52]
Type: A1 Application with search report 
No.:EP2861233
Date:22.04.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 27.12.2013 takes the place of the publication of the European patent application.
[2015/17]
Type: B1 Patent specification 
No.:EP2861233
Date:06.11.2019
Language:EN
[2019/45]
Search report(s)International search report - published on:US27.12.2013
(Supplementary) European search report - dispatched on:EP04.09.2015
ClassificationIPC:A61K9/70, A61K31/57, A61K31/565, A61K47/14, A61K45/06
[2015/41]
CPC:
A61K47/14 (EP,US); A61K31/565 (EP,US); A61K31/566 (US);
A61K31/57 (EP,US); A61K31/573 (US); A61K45/06 (EP,US); (+)
C-Set:
A61K31/565, A61K2300/00 (EP,US);
A61K31/57, A61K2300/00 (US,EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/17]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:TRANSDERMALE HORMONERSATZTHERAPIEN[2015/17]
English:TRANSDERMAL HORMONE REPLACEMENT THERAPIES[2015/17]
French:TRAITEMENT TRANSDERMIQUE DE SUBSTITUTION HORMONALE[2015/17]
Entry into regional phase14.10.2014National basic fee paid 
14.10.2014Search fee paid 
14.10.2014Designation fee(s) paid 
14.10.2014Examination fee paid 
Examination procedure14.10.2014Examination requested  [2015/17]
04.04.2016Amendment by applicant (claims and/or description)
15.05.2019Communication of intention to grant the patent
20.09.2019Fee for grant paid
20.09.2019Fee for publishing/printing paid
20.09.2019Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  15.05.2019
Opposition(s)07.08.2020No opposition filed within time limit [2020/42]
Fees paidRenewal fee
30.06.2015Renewal fee patent year 03
31.03.2016Renewal fee patent year 04
28.06.2017Renewal fee patent year 05
25.06.2018Renewal fee patent year 06
28.06.2019Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU18.06.2013
AL06.11.2019
AT06.11.2019
CY06.11.2019
CZ06.11.2019
DK06.11.2019
EE06.11.2019
ES06.11.2019
FI06.11.2019
HR06.11.2019
IT06.11.2019
LT06.11.2019
LV06.11.2019
MC06.11.2019
MK06.11.2019
MT06.11.2019
NL06.11.2019
PL06.11.2019
RO06.11.2019
RS06.11.2019
SE06.11.2019
SI06.11.2019
SK06.11.2019
SM06.11.2019
TR06.11.2019
BG06.02.2020
NO06.02.2020
GR07.02.2020
IS06.03.2020
PT06.03.2020
IE18.06.2020
LU18.06.2020
BE30.06.2020
CH30.06.2020
LI30.06.2020
[2022/32]
Documents cited:Search[X]EP0279977  (ALZA CORP [US]) [X] 1,19 * example -; table I *;
 [Y]WO9011064  (CYGNUS RESEARCH CORP [US]) [Y] 1-24 * page 13, paragraphs 1-2 *;
 [Y]WO9743989  (DIVERSIFIED PHARMACEUTICALS IN [US], et al) [Y] 1-24* page 38, line 20 - page 42, line 22 *;
 [Y]WO0050007  (LIPOCINE INC [US]) [Y] 1-24 * page 65; example 66 *;
 [X]WO0187276  (SAMYANG CORP [KR], et al) [X] 1,19 * examples 2,3 *;
 [Y]US2003077297  (CHEN FENG-JING [US], et al) [Y] 1-24 * examples 38-47 *
International search[A]US4384096  (SONNABEND LAWRENCE F);
 [A]US6294192  (PATEL MAHESH V [US], et al);
 [A]US2005042268  (ASCHKENASY CHAIM [IL], et al);
 [A]US2006134188  (PODHAISKY HANS-PETER [DE], et al);
 [X]US2007264349  (LEE ROBERT [US], et al)
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.